KUALA LUMPUR, 27th April, 2017 – StemLife Berhad, a stem cell bank founded in 2001 and licensed by the Ministry of Health Malaysia under the Private Healthcare Facilities and Services (PHFS) Act 1998 is no longer a counter on Bursa Malaysia stock exchange. StemLife , the pioneer in offering cord blood banking became a listed entity on the MESDAQ (now known as ACE) market in 2006, and has since been in the forefront of medical breakthroughs pertaining to cord blood stem cell and cord lining. In view of its growth potential in Malaysia, after two rounds of takeover exercises, Cordlife Group Limited (CGL) - which is listed on the Singapore Stock Exchange (SGX) - accumulated more than 90% shareholding in StemLife Berhad by February 2017, resulting it to be taken off the ACE Market listing. (From Left to Right) Dr. Daniel Lim Say Liang, Deputy Technical Director of Cordlife Group Limited, Ms Yap Eng Gee, Chief Executive Officer of StemLife Berhad and Dr Wong Chiang Yin, Executi